The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp
Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp
Never miss any important news. Subscribe to our newsletter.
Never miss any important news. Subscribe to our newsletter.
Recent News
How Oct. 7 Changed American Jews
October 6, 2024
Supreme Court Returns With Possible Election Cases Looming
October 6, 2024
Trump’s Rambling Speeches Reinforce Question of Age
October 6, 2024
In Salt Lake City, Sports Drive a New Vision for Downtown
October 6, 2024